Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 13/20 | 0.55 |
| ▸ | CA1 | P00915 | 13/20 | 0.55 |
| ▸ | CA2 | P00918 | 13/20 | 0.55 |
| ▸ | CA4 | P22748 | 6/20 | 0.54 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.52 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.52 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6540370 | 0.93 | ESR1 (0.51) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540822 | 0.90 | TAS2R14 (0.57) | CA12CA1CA2CA4TAS2R14 | |
| SCHEMBL6539996 | 0.90 | HTR6 (0.51) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6541013 | 0.89 | CA12 (0.50) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540792 | 0.85 | CA12 (0.55) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540922 | 0.82 | L3MBTL1 (0.48) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6799685 | 0.82 | ESR1 (0.45) | CA12CA1CA2TAS2R14ESR1 | |
| SCHEMBL7228409 | 0.82 | MEN1 (0.61) | CA12CA1CA2CA4RCE1 | |
| SCHEMBL6540096 | 0.81 | LPAR1 (0.54) | CA12CA1CA2CA4 | |
| SCHEMBL14362172 | 0.81 | DPP4 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | CA12 1959/4885CA1 2450/4885CA2 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.